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Background/aim: Insulin sensitivity and β-cell function during Ramadan fasting in healthy male subjects have not been investigated
so far. We assessed the changes of these and other metabolic parameters to judge the potential metabolic benefits of Ramadan fasting.
Materials and methods: Twenty-four healthy males of Turkish origin living in Germany, with normal glucose tolerance, participated in
this study during Ramadan of 2009; 19 who completed fasting were analyzed. Blood was drawn at sunset after a period of fasting lasting
approximately 15 h on days 0, 16, and 30 of Ramadan, as well as 7 and 28 days later. Insulin sensitivity (Homeostasis Model Assessment,
HOMA), β-cell function, and other parameters were assessed.
Results: Ramadan fasting was associated with a significant reduction (–) or increment (+) for the following variables: insulin sensitivity
(–20%; P = 0.04), β-cell function (+10%; P = 0.049), high-density lipoprotein cholesterol (–23%; P = 0.0003), low-density lipoprotein
cholesterol (+14%; P = 0.007), nonesterified fatty acids (–62%; P < 0.0001), resistin (–20%; P = 0.01), adiponectin (+16%; P = 0.003),
and glucagon (–21%; P = 0.01). C-peptide, insulin, leptin, triglyceride, and very low-density lipoprotein cholesterol concentrations were
not significantly changed.
Conclusion: Ramadan fasting is associated with transiently impaired insulin sensitivity, compensated for by an increased β-cell
function. However, the pattern of insulin resistance-mediating adipocytokines suggests a potentially beneficial metabolic effect of
Ramadan fasting.
Key words: Insulin sensitivity, β-cell function, adiponectin, leptin, resistin, Ramadan fasting

1. Introduction
Many efforts have been undertaken to elucidate the
changes of metabolic parameters during Ramadan fasting
in healthy subjects, including the following: 1) Regarding
blood glucose, significant reductions (1,2) or no significant
changes (3,4) have been reported. 2) Insulin was not
changed (3,5). 3) For high-density lipoprotein (HDL)
as well as low-density lipoprotein (LDL) cholesterol
concentrations, conflicting data have been published,
(6,7), and no significant changes were described for very
low-density lipoprotein (VLDL) cholesterol (4,7,8). 4)
Concerning triglycerides, conflicting data have been
presented (3,4,6,7). 5) Regarding thyroid parameters,
Fadail et al. reported a significant rise in total thyroxin
and a reduction in triiodothyronine (5), and Sajid et al.
showed a significant increment in thyrotropin (9). 6)
For cortisol, Al-Hadramy et al. reported a reduction and
Bahijri et al. reported an increase in concentrations (10,11).
7) With respect to renal parameters, conflicting urea
concentrations have been reported (2,3,7), and Maislos
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et al. found no significant changes regarding creatinine
concentrations (7). Several studies showed a reduction
(3,8,12), and other studies no change, in body weight or
body mass index (BMI) (4,13) during Ramadan fasting.
8) Blood pressure during Ramadan fasting has been
found unchanged (14), or systolic as well as diastolic
blood pressures were reported decreased (15). Adlouni et
al. reported an increase (6) and Bouhlel et al. a significant
decrease (3) in total calorie intake during Ramadan
fasting.
All adult Muslims, with some exceptions (e.g., illness,
gestation, menstruation, and travel), are requested to fast
30 days from early dawn until sunset during the ninth
lunar calendar every year.
Metabolic parameters are usually determined in
the morning. However, in studies during Ramadan the
parameters are obtained before sunset in the evening. The
equivalence/comparability of fasting parameters obtained
in the morning and in the evening, respectively, has not
been investigated so far.
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To our knowledge, insulin sensitivity, β-cell function,
glucagon, nonesterified fatty acids, and adipocytokines
(adiponectin, leptin, and resistin) have not been examined
during and after Ramadan fasting in healthy subjects with
normal glucose tolerance so far.
Therefore, in the present study we investigated the
changes in insulin sensitivity, β-cell function, and other
metabolic factors during and after Ramadan fasting in
healthy men with normal glucose tolerance.
2. Materials and methods
2.1. Protocol
The study protocol was approved by the ethics committee
of the Georg-August University of Göttingen (registration
number 23/1/09) on 18 May 2009, and the study was
carried out in accordance with the Declaration of Helsinki.
2.2. Subjects
We recruited 24 healthy male migrants of Turkish origin
in Germany who had decided to participate in Ramadan
fasting independent from our study. Inclusion criteria:
Healthy male subject with normal oral glucose tolerance,
aged 18–75 years. Exclusion criteria: BMI of <18.5 or ≥35
kg/m2, any type of diabetes, impaired glucose tolerance,
impaired fasting glucose , endocrine disorders influencing
glucose metabolism, treatment with drugs with influence
on glucose metabolism (e.g., hydrochlorothiazide,
β-blockers, diazoxide, interferon-alpha, cyclosporine,
glucocorticoids, nicotinic acid, statins, and fibrates), any
interruption of Ramadan fasting, renal insufficiency at
screening [estimated glomerular filtration rate (eGFR) of
<60 mL/min], and overt hyper- or hypothyroidism.
2.3. Procedures
The volunteers participated at the following visits: Visit
1, screening in the morning, 0800–0900 hours (between
5 June and 19 August 2009), after a period of at least 12
h without nutrient intake. Visit 2 (day 0), beginning of
Ramadan fasting [20 August 2009, 1940–2040 hours, at
sunset (“iftar”)] (to enable the participants to take their
meal at sunset on the first day of Ramadan fasting (21
August 2009) together with their families at home, we
started the fasting 1 day earlier than usual). Visit 3 (day 16),
in the middle of the Ramadan fasting period (5 September
2009, 1905–2005 hours). Visit 4 (day 30), end of Ramadan
fasting (19 September 2009, 1835–1935 hours). Visit
5 (day 37), 7 days after the end of Ramadan fasting (26
September 2009, 1820–1920 hours). Visit 6 (day 58), 28
days after the end of Ramadan fasting (17 October 2009,
1730–1830 hours). During Ramadan fasting and thereafter
the examinations were at sunset after a fasting period.
The duration of the fasting period was from 0440 to
2040 hours on day 0, and thereafter it shifted with the
exact timing of dawn and sunset until day 30 of Ramadan,

when fasting started at 0507 hours and finished at 1935
hours. The daily fasting period varied between 16 h in the
beginning and 14.5 h at the end of Ramadan fasting.
At screening, an oral glucose tolerance test was
performed using an Accu Chek-Dextro O.G-T., containing
75 g of glucose (Roche Diagnostics, Mannheim, Germany).
At every visit insulin sensitivity [homeostasis model
assessment (HOMA)2-%S; primary endpoint], β-cell
function [HOMA2-%B; HOMA 2 model (16)], insulin,
C-peptide, glucose, glucagon, adiponectin, leptin,
resistin, cortisol, lipid, renal, thyroid, and anthropometric
parametric parameters were assessed.
2.3.1. Blood specimens
For determination of glucose, tubes containing sodium
fluoride (Glukose-Fluorid, Sarstedt Monovetten, Sarstedt
AG & Co., Nümbrecht, Germany) were used. For the
determination of HDL, LDL, and VLDL cholesterol,
we separated a serum aliquot, which was stored at 4 °C
and studied on the same day or within 2 days. For the
determination of other parameters, serum was frozen in
aliquots at –80 °C and parameters were analyzed after
the last visit (all in the same assay run). Glucose was
determined immediately on the day of sample collection;
supernatant was stored as aliquots at –80 °C. For glucagon
determination per mL of plasma 50 µL of aprotinin
(Trasylol, 10,000 KIU/mL, Bayer AG, Leverkusen,
Germany) was added to inhibit degradation of glucagon.
2.3.2. Laboratory determinations
Glucose was measured using an enzymatic-amperometric
method (Biosen S-line, EKF-diagnostic GmbH, Barsleben,
Magdeburg, Germany). Insulin, C-peptide, thyrotropin
(TSH), free triiodothyronine, free thyroxine, and cortisol
were measured using an immunoassay system (Siemens
Healthcare Diagnostics ADVIA Centaur CP-System;
Siemens Healthcare Diagnostics Ltd., Camberley, UK).
Glucagon concentrations in plasma were measured
after extraction of plasma with 70% ethanol (v/v, final
concentration). The antibody employed (code no. 4305) is
directed against the C-terminus of the glucagon molecule
and therefore mainly measures glucagon of pancreatic
origin (17). Standards were human glucagon and the
tracer was monoiodinated human glucagon (both gifts
from NovoNordisk, Bagsværd, Denmark). Sensitivity
and detection limit are below 1 pmol/L, intraassay
coefficient of variation is below 6% at 20–30 pmol/L, and
recovery of standard, added to plasma before extraction,
is about 100% when corrected for losses inherent in the
plasma extraction procedure. Adiponectin and resistin
were measured using an enzyme immunoassay system
(Mediagnost ELISA; Mediagnost, Reutlingen, Germany).
Leptin was measured using a radioimmunoassay
system (Mediagnost Leptin RIA CT R44; Mediagnost).
Triglycerides, nonesterified fatty acids (NEFAs), urea, and
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creatinine were measured using an enzymatic bichromatic
endpoint measurement (Siemens Healthcare Diagnostics
Dimension clinical chemistry system; Siemens Healthcare
Diagnostics Ltd.). Total cholesterol was measured using
an enzymatic polychromatic endpoint measurement
(Siemens Healthcare Diagnostics Dimension clinical
chemistry system; Siemens Healthcare Diagnostics Ltd.).
HDL, LDL, and VLDL cholesterol were measured using
a kit for determination of lipoproteins (Lipidophor
Tris All in 12 (Technoclone GmbH, Vienna, Austria).
Sodium and potassium were measured using the Siemens
Healthcare Diagnostics Dimension QuickLYTE Integrated
Multisensor System Kit (Siemens Healthcare Diagnostics
Ltd.). The eGFR was estimated using the Cockcroft–Gault
formula.
Insulin sensitivity (HOMA2-%S) and β-cell function
(HOMA2-%B) were calculated using the HOMA
Calculator [HOMA2 Calculator v2.2, Diabetes Trials Unit,
University of Oxford, a software implementation of the
HOMA2 model), downloaded from http://www.dtu.ox.ac.
uk/homa (16)]. Briefly, insulin sensitivity was calculated
from simultaneously determined plasma glucose and
serum insulin. For the calculation of β-cell function,
simultaneously determined plasma glucose and C-peptide
were used (16).
2.4. Statistical analysis
Subject characteristics as well as results are presented as
mean ± standard deviation (SD). The descriptive analysis
(mean, SD, range) was performed using IBM SPSS
Statistics Release 19.0.0.1 (IBM Corporation, Armonk,
NY, USA). Normal distribution for all parameters was
checked by the Kolmogorov–Smirnov test. For normally
distributed variables, analysis of variance (ANOVA) was
performed.
ANOVA with repeated measures was performed for
the primary endpoint (insulin sensitivity) as well as for
the secondary endpoints (other variables) for visit 2 to
visit 6 using Statistica (StatSoft Inc., Hamburg, Germany,
Version 10.0). If significant, values at single time points
were compared to the value measured on day 0 using
Duncan’s post hoc test. For linear regression analyses we
used GraphPad Prism, version 5.02 (GraphPad Software
Inc., La Jolla, CA, USA). A 2-sided P value of <0.05 was
taken to indicate significant differences.
3. Results
Thirty-one volunteers were screened. Seven of them had
to be excluded because of violations of inclusion/exclusion
criteria. Twenty-four subjects participated in the study.
Five of them could not be analyzed because of incomplete
data or interruption of Ramadan fasting. Nineteen subjects
completed the study and were analyzed.

1012

Characteristics of the volunteers at screening (before
Ramadan fasting, blood drawn in the morning) and at
the beginning of Ramadan fasting (day 0, blood drawn at
sunset) are presented in the Table.
3.1. Anthropometric parameters
Four weeks after the beginning of Ramadan fasting, body
weight decreased (–1%, P = 0.046). Body mass index
significantly increased (+1%, P = 0.04) 4 weeks after the
end of Ramadan fasting. Waist measurement and waistto-hip ratio did not significantly change during and after
Ramadan fasting.
3.2. Comparability of fasting metabolic parameters
obtained in the morning and at sunset
There were some significant changes between
determinations at dawn (screening) and sunset (day 0) of
some parameters. At sunset, insulin sensitivity (+70%),
NEFAs (+150%), and HDL cholesterol (+ 43%) were
higher, while insulin (–31%), C-peptide (–23%), leptin
(–19%), and TSH (–33%) decreased. A comparison of all
parameters and the results of linear regression analyses
are presented in the Table. We found a significant positive
linear correlation between the results in the morning and
sunset for body weight, BMI, waist measurement, and
the waist-to-hip ratio. There was a significant difference
between concentrations in the morning and at sunset
for body weight and BMI. For the waist measurement
and waist-to-hip ratio, we found no significant difference
between concentrations in the morning and at sunset. We
found a significant positive linear correlation between
the results in the morning and at sunset for glucagon,
β-cell function, insulin, and C-peptide (Figure 1). There
was a significant difference between concentrations at
dawn and sunset for plasma glucose, insulin, C-peptide,
and insulin sensitivity (HOMA2-%S). For β-cell function
(HOMA2-%B) and glucagon we found no significant
difference between concentrations at dawn and sunset. We
found significant linear correlations between the results
in the morning and at sunset for free thyroxine. There
was no significant difference between concentrations in
the morning and at sunset for free thyroxine. We found a
significant positive linear correlation between the results
at dawn and sunset for serum creatinine and eGFR. There
was a significant difference between concentrations in the
morning and at sunset for serum creatinine, eGFR, and
sodium. For urea and potassium we found no significant
difference between concentrations in the morning and at
sunset (Table).
3.3. Parameters characterizing insulin sensitivity and
secretion, glucose metabolism, and glucagon
Four weeks after the beginning of Ramadan fasting,
insulin sensitivity decreased (–20%) significantly from
129.2 ± 71.8% (baseline) to 103.1 ± 43.2% (P = 0.04). Four
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Table. Anthropometric data and laboratory parameters of completers (healthy men, n = 19) at screening and on day 0 of Ramadan
fasting.
Screening (in the morning)

Day 0 (in the evening)

Mean ± SD

Range

Mean ± SD

Range

Difference
of mean
(%)

Age [years]

36 ± 9

20–49

36 ± 9

20–49

0.0

Body weight [kg]

89 ± 12

71–108

88 ± 11

71–106

–1.1

Parameter [unit]

Normal
range

P value†

Linear regression
r²

P value‡

0.009

0.99

<0.0001

BMI [kg/m ]

18.5–24.9

28.8 ± 3.4

22.9–34.6

28.9 ± 3.2

23.0–34.1

0.3

0.007

0.99

<0.0001

Waist measurement [cm]

<94

97 ± 9.8

81–120

96 ± 8,6

82–115

–1.0

0.27

0.93

<0.0001

Hip measurement [cm]

<102

99 ± 7.8

88–112

98 ± 7.0

88–113

–1.0

0.26

0.82

<0.0001

Waist-to-hip ratio

<0.9

0.98 ± 0.05

0.9–1.1

0.98 ± 0.04

0.9–1.1

0.0

0.79

0.79

<0.0001

Systolic blood pressure [mmHg]

<140

122 ± 10

98–138

124 ± 13

100–149

2.5

0.32

0.09

0.22

Diastolic blood pressure [mmHg]

<90

76 ± 11

61–97

78 ± 10

60–97

2.6

0.79

0.34

0.11

Heart rate [beats/min]

60–80

70 ± 10

56–93

77 ± 11

63–99

10.0

0.002

0.38

0.005

Fasting glucose (in plasma) [mg/dL]

<100

94 ± 4

87–100

84 ± 8

68–102

–10.6

<0.0001

0.17

0.08

2-h glucose in plasma [mg/dL]

<140

89 ± 20

61–135

Insulin [mU/L]

3–25

11.1 ± 4.6

4.2–20.3

7.7 ± 4.1

2.6–16.7

–30.6

0.0005

0.47

0.001

C-peptide [nmol/L]

0.27–1.27

0.61 ± 0.12

0.38–0.85

0.47 ± 0.16

0.24–0.75

–23.0

0.0004

0.28

0.03

10.6 ± 6.0

5–30

11.2 ± 4.9

6–23

5.7

0.43

0.73

<0.0001

2

Glucagon [pmol/L]
Insulin sensitivity (HOMA2-%S) [%]

100

76.1 ± 16.3

53.4–119.7

129.2 ± 71.8

44–291

69.8

0.004

0.17

0.08

β-cell function (HOMA2-%B) [%]

100

107.4 ± 16.7

84.6–145.3

112.5 ± 31.2

74–208

4.7

0.31

0.60

<0.0001

HDL cholesterol [mg/dL]

>35

23.2 ± 8.7

10–39

33.2 ± 7.7

16–45

43.1

0.0002

0.15

0.11

LDL cholesterol [mg/dL]

<130

135 ± 43

56–249

149 ± 43

96–291

10.9

0.01

0.73

<0.0001

27 ± 18

6–70

21 ± 15

7–57

–25.2

0.06

0.38

0.005

VLDL cholesterol [mg/dL]
Nonesterified fatty acids [mmol/L]

0.1–0.6

0.3 ± 0.1

0.1– 0.6

0.7 ± 0.2

0.3–1.2

150.0

<0.0001

0.18

0.07

Triglycerides [mg/dL]

50–150

227 ± 165

46–753

208 ± 159

71–685

–8.4

0.32

0.77

<0.0001

Adiponectin [µg/mL]

1.3–11.6

3.0 ± 1.3

0.9–5.9

3.1 ± 1.4

0.8–5.8

3.3

0.38

0.80

<0.0001

Leptin [ng/mL]

1–56

5.7 ± 3.8

1.8–15.6

4.6 ± 3.8

1.0–13.4

–19.3

0.003

0.89

<0.0001

Resistin [ng/mL]

2.8–12.1

3.4 ± 1.3

1.9–7.2

3.9 ± 1.4

1.7–6.6

14.7

0.07

0.30

0.02

Cortisol [µg/dL]

4.3–22.4

17.2 ± 5.6

7.9–26.1

11.8 ± 5.9

2.1–22.9

–3.4

0.004

0.04

0.36

TSH [mU/L]

0.35–5.5

1.5 ± 0.8

0.4–3.2

1.0 ± 0.5

0.2–1.8

–33.3

0.009

0.22

0.04

fT3 [pg/mL]

2.3–4.2

4.1 ± 0.4

3.3–4.8

4.0 ± 0.3

3.4–4.5

–2.4

0.40

0.37

0.005

fT4 [ng/dL]

0.9–1.8

1.5 ± 0.2

1.1–1.9

1.5 ± 0.3

1.0–1.8

0.0

0.72

0.69

<0.0001

Creatinine [mg/dL]

0.8–1.3

0.9 ± 0.1

0.6–1.1

1.0 ± 0.1

0.7–1.2

11.1

0.04

0.62

<0.0001

*eGFR [mL/min]

>60

139 ± 34

98–228

132 ± 32

90–199

–5.0

0.04

0.82

<0.0001

Urea [mg/dL]

15.0–38.5

30.3 ± 6.5

21–43

32 ± 5

26–46

5.6

0.43

0.006

0.76

Sodium [mmol/L]

136–148

140 ± 2

137–144

142 ± 2

140–148

1.4

0.006

0.003

0.82

Potassium [mmol/L]

3.5–5.5

4.2 ± 0.3

3.7–4.8

4.4 ± 0.3

3.8–4.9

4.8

0.09

0.16

0.09

*: eGFR with Cockcroft–Gault formula. SD = Standard deviation. †: P-value for screening versus day 0. ‡: P-value for the correlation between screening and day 0.
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90 100 110
Glucose [mg/dL]
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Figure 1. Regression analysis of data obtained in the morning (at screening, fasting)
and in the evening (on day 0 of the Ramadan fasting) in 19 healthy men for β-cell
function (A), insulin sensitivity (B), glucagon (C), insulin (D), C-peptide (E), and
glucose (F). The P-value indicates the significance of the coefficient of determination
(r2) for the linear regression.

weeks after the end of Ramadan fasting, insulin sensitivity
increased to 143.6 ± 56.4% (P = 0.22 compared to day 0).
Fourteen days after the beginning of Ramadan fasting,
β-cell function (HOMA2-%B) increased significantly
(+10%) from 112.5 ± 31.2% to 124.2 ± 26.8 (P = 0.049).
Glucagon concentrations decreased within 2 weeks
(–18%, P = 0.01) after the beginning of Ramadan fasting
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and remained significantly under baseline until 4 weeks
after the end of Ramadan fasting (Figure 2).
3.4. Lipid parameters
Nonesterified fatty acids significantly decreased 2 weeks
after the beginning of Ramadan fasting from 0.71 ± 0.23
mmol/L to a minimum of 0.27 ± 0.14 mmol/L (–62%; P
<0.0001) and this reduction below baseline concentrations
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Figure 2. Parameters characterizing insulin sensitivity and β-cell function and glucagon during and after Ramadan fasting
in 19 healthy men (A–F). Data are presented as mean ± SD. The P-value indicates differences over time (ANOVA repeated
measures); asterisks show significant difference (P < 0.05, Duncan’s post hoc test) compared to the beginning of Ramadan
fasting, day 0.

persisted significantly throughout the follow-up period.
Four weeks after the beginning of Ramadan fasting, LDL
cholesterol significantly increased (+14%, P = 0.007)
and HDL cholesterol significantly decreased (–23%, P =
0.0003) (Figure 3). VLDL cholesterol and triglyceride
concentrations did not change significantly.
3.5. Adipocytokines
Two weeks after the beginning of Ramadan fasting, resistin
decreased significantly (–18%, P = 0.01) and remained
significantly below baseline during the follow-up period.
Adiponectin increased significantly 1 week after the end of
Ramadan fasting (+16%, P = 0.003). Leptin concentrations
did not change significantly during and after Ramadan
fasting (Figure 4).

3.6. Thyroid hormones
Two weeks after the beginning of Ramadan fasting,
TSH significantly increased (+20%, P = 0.03) and free
thyroxine significantly decreased (–7%, P = 0.007). Free
triiodothyronine concentrations did not significantly
change during Ramadan fasting. One week after the end
of Ramadan fasting, cortisol decreased (–27%, P = 0.01
compared to day 0).
3.7. Circulatory parameters
Systolic (–6%, P = 0.005) and diastolic (–8%, P = 0.01)
pressure decreased significantly 4 weeks after the beginning
of Ramadan fasting.
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Figure 3. Lipid parameters and adipocytokines during and after Ramadan fasting in 19 healthy men (A–F). Data are
presented as mean ± SD. The P-value indicates differences over time (ANOVA repeated measures); asterisks show
significant difference (P < 0.05, Duncan’s post hoc test) compared to the beginning of Ramadan fasting, day 0.

3.8. Renal parameters
One week after the end of Ramadan fasting, plasma
creatinine significantly decreased (–5%, P = 0.01) and
remained significantly below baseline concentrations
(Table) until 4 weeks after the end of Ramadan fasting.
The eGFR significantly increased (+6%, P = 0.03) 1 week
after the end of Ramadan fasting and reached a maximum
4 weeks after the end of Ramadan fasting. Urea (–16%, P =
0.01) and sodium (–1%, P = 0.002) significantly decreased
2 weeks after the beginning of Ramadan fasting.
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4. Discussion
The fasting results that we observed in the morning and
at sunset were not generally different, so reliable results
can be obtained after Ramadan fasting in the evening.
The ratios (in the morning versus at sunset) for insulin
(1.4) and C-peptide (1.3) were not identical. However, we
cannot explain the small difference.
In this study we showed, for the first time, that
compared to baseline concentrations at the begin of
Ramadan fasting, insulin sensitivity significantly decreased
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Figure 4. Resistin (A), adiponectin (B), and leptin (C)
concentrations during and after Ramadan fasting in 19 healthy
men. Data are presented as mean ± SD. The P-value indicates
differences over time (ANOVA repeated measures); asterisks
show significant difference (P < 0.05, Duncan’s post hoc test)
compared to the beginning of Ramadan fasting, day 0.

(–20%) against expectations, β-cell function significantly
increased (+10%), and glucagon (–21%) and resistin
(–20%) significantly decreased during Ramadan fasting,
while adiponectin increased (+16%) 1 week after the

end of Ramadan fasting and leptin showed no significant
changes during as well as after Ramadan fasting in healthy
male subjects.
Shariatpanahi et al. found that Ramadan fasting
is associated with improvement in insulin sensitivity
(1/HOMA-IR) in patients with metabolic syndrome
(18). Yarahmadi et al. described that insulin resistance
significantly decreased during Ramadan fasting in patients
with type 2 diabetes (19).
Heilbronn et al. investigated the insulin sensitivity
in healthy volunteers after 3 weeks of alternating fasting.
They found a significant increase in insulin sensitivity
after the end of such a fasting pattern (20). Fasting periods
seem to influence insulin sensitivity beneficially. However,
it has been shown that uninterrupted 72-h fasting (21) and
4-day fasting (22) lead to worsening insulin resistance . It
is believed that insulin resistance arising in skeletal muscle
induces an impairment of glucose tolerance after fasting
for long periods (22,23).
Regarding insulin sensitivity, our results in healthy
subjects are in line with the findings of Bahijri et al.
obtained in healthy subjects (10), with the findings of
Shariatpanahi et al. obtained in subjects with metabolic
syndrome (18), with the findings of Unalacak et al.
obtained in nonobese healthy male subjects (24), and
with the results of Yarahmadi et al. in patients with type
2 diabetes (19).
The reason for the impairment of insulin sensitivity
during Ramadan fasting, although NEFAs and glucagon
concentrations significantly decreased, is not obvious. One
potential explanation may be that our method of assessing
insulin sensitivity (HOMA2 model) was not optimal. More
elaborate methods (e.g., the hyperinsulinemic euglycemic
clamp) might elicit different results.
During Ramadan fasting we found a temporary
increase of β-cell function, possibly compensatory to the
decreased insulin sensitivity. This result is consistent with
the previous findings of hyperinsulinemia in patients with
insulin resistance (25).
During Ramadan fasting we found a continuous
decrease of glucagon, lasting after the Ramadan fasting. The
relation of the dramatic decrease in NEFA concentrations
and glucagon is not understood yet; there are conflicting
data. In various in vitro studies with pancreatic islets it
was shown that NEFAs lead to an impairment of glucagon
secretion in rats (26) and in mice (27). Gerich et al. found
that the heparin-induced elevation of NEFA leads to an
impairment of glucagon in healthy subjects as well as
in subjects with type 1 diabetes (28). Recently, in an in
vitro study, it was shown that NEFAs stimulate glucagon
secretion in pancreatic islets (29). Regarding NEFAs during
Ramadan fasting in healthy volunteers, there are no data in
the literature. In the present study we found an impressive
decrease of NEFAs 2 weeks after the beginning of Ramadan
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fasting. We suppose that this pattern of NEFAs has a
beneficial influence on carbohydrate metabolism, since
increased NEFA concentrations may induce peripheral
as well as hepatic insulin resistance (30,31). This can be
explained by the following mechanisms (31): 1) NEFAs are
increased in most obese subjects, 2) temporarily increased
NEFAs can suppress the insulin-stimulated glucose intake
in healthy subjects as well as in subjects with diabetes (31).
In the Randle cycle, NEFAs are competing with glucose
and influencing the glucose metabolism unfavorably
(32). Furthermore, NEFAs have disadvantageous effects
regarding insulin uptake into the liver and can lead to
an enhancement of hepatic glucose release (33). Due to
the impressive decrease of NEFAs in our study it may be
supposed that Ramadan fasting can be beneficial in the
sense of helping prevent metabolic syndrome in healthy
men, because this reduction in NEFA concentrations is
probably associated with an enhanced insulin sensitivity
in adipose tissue and the liver. The pathway leading to
a decrement of NEFAs is probably one of the important
points for a potentially beneficial effect of Ramadan
fasting. Regarding LDL cholesterol concentrations during
Ramadan fasting in healthy subjects, conflicting data have
been published (3,6,7). The reason for the increase of LDL
cholesterol and the decrease of HDL cholesterol in our
study is unclear. However, the findings of Ziaee et al. (8)
are in line with our LDL and HDL cholesterol results.
We hypothesize that Ramadan fasting, with daily fasting
periods of approximately 15 h, leads to an enhancement
of the insulin sensitivity in adipose tissue and in the liver,
which may not be measured adequately by the HOMA2
parameters.
We found a significant rise in adiponectin
concentrations 1 week after the end of Ramadan fasting.
Adipose tissue is involved relevantly in the regulation
of energy balance and secretes biologically active
adipocytokines, e.g., adiponectin (34), leptin (35), and
resistin (36). Adiponectin improves insulin sensitivity
(34), e.g., it has an insulin-sensitizing effect in the liver
(37,38) and in skeletal muscle (39). Regarding leptin
concentrations, our results in healthy subjects are in line
with the findings of Khafaji et al. obtained in stable cardiac
patients (40). They found no significant changes of leptin
concentrations during and after Ramadan fasting. Leptin
serum concentrations are positively correlated with body
fat mass and with BMI, as well as with fasting insulin

concentrations (41). Resistin can cause or worsen insulin
resistance (32). In subjects with metabolic syndrome,
resistin concentrations are elevated (42). In obese mice
(diet-induced) with insulin resistance and hyperglycemia,
administration of antiresistin antibodies is associated
with a decrease of blood glucose and an improvement
of insulin sensitivity, suggesting a causal role of resistin
in the genesis of insulin resistance (32). The decreased
resistin concentrations during and after Ramadan fasting
in our study tend to support our primary hypothesis
that Ramadan fasting may improve insulin sensitivity.
However, direct measurement of insulin sensitivity did not
confirm this assumption.
A limitation of our study is that we did not document
the daily calorie intake and the composition of the meals.
In further studies on Ramadan fasting, we recommend the
acquisition of such data.
In conclusion, contrary to our original assumption,
Ramadan fasting led to a transient reduction in insulin
sensitivity, compensated for by improved β-cell function,
with no significant change in glucose concentrations.
However, favorable changes of insulin resistance mediating
adipocytokines, lasting up to 4 weeks after Ramadan
fasting, suggest a potentially beneficial metabolic effect.
Further studies are needed to explain the mechanism of
reduced insulin sensitivity despite a fall in NEFAs and
reduction in glucagon.
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